FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163046315> ?p ?o ?g. }

• W3163046315 abstract "Abstract Background COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by the FDA to treat HCV infection. This study investigates the efficacy of Sofosbuvir/ledipasvir as a treatment for patients with moderate COVID-19 infection.. Methods This is a single-blinded parallel-randomized controlled trial. The participants were randomized equally into the intervention group received Sofosbuvir/ledipasvir (S.L. group), and the control group received Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary outcomes were the cure rate over time and the incidence of serious adverse events. The secondary outcomes included the laboratory findings. Results Two hundred and fifty patients were divided equally into each group. Both groups were similar regarding gender, but age was higher in the S.L. group (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only 51 (40.8%) patients were cured in the OCH group. The cure rate was significantly higher in the S.L. group (RR=1.75, p<0.001). Kaplan-Meir plot showed a considerably higher cure over time in the S.L. group (Log-rank test, p=0.032). There were no deaths in the S.L. group, but there were six deaths (4.8%) in the OCH group (RR=0.08, p=0.013). Seven patients (5.6%) in the S.L. group and six patients (4.8%) in the OCH group were admitted to ICU (RR=1.17, P=0.776). There was no significant difference between treatment groups regarding Total Leukocyte Count, Neutrophils count, Lymph and Urea. Conclusion Sofosbuvir/ledipasvir is suggestive of being effective in treating patients with moderate COVID-19 infection. Further studies are needed to compare Sofosbuvir/ledipasvir with the new treatment protocols." @default.
• W3163046315 created "2021-05-24" @default.
• W3163046315 creator A5001774374 @default.
• W3163046315 creator A5002788561 @default.
• W3163046315 creator A5003776025 @default.
• W3163046315 creator A5008359642 @default.
• W3163046315 creator A5015765270 @default.
• W3163046315 creator A5019022859 @default.
• W3163046315 creator A5020347222 @default.
• W3163046315 creator A5028356335 @default.
• W3163046315 creator A5031356675 @default.
• W3163046315 creator A5041881696 @default.
• W3163046315 creator A5045767035 @default.
• W3163046315 creator A5047329575 @default.
• W3163046315 creator A5047891924 @default.
• W3163046315 creator A5051871773 @default.
• W3163046315 creator A5057785190 @default.
• W3163046315 creator A5062734602 @default.
• W3163046315 creator A5063111673 @default.
• W3163046315 creator A5067167406 @default.
• W3163046315 creator A5077983454 @default.
• W3163046315 creator A5079525487 @default.
• W3163046315 creator A5079571574 @default.
• W3163046315 creator A5081565688 @default.
• W3163046315 creator A5082379608 @default.
• W3163046315 creator A5087978819 @default.
• W3163046315 creator A5089247413 @default.
• W3163046315 date "2021-05-21" @default.
• W3163046315 modified "2023-09-27" @default.
• W3163046315 title "Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial" @default.
• W3163046315 cites W1978349722 @default.
• W3163046315 cites W2072658090 @default.
• W3163046315 cites W2087251383 @default.
• W3163046315 cites W2397520238 @default.
• W3163046315 cites W3001118548 @default.
• W3163046315 cites W3004096029 @default.
• W3163046315 cites W3007386177 @default.
• W3163046315 cites W3007964452 @default.
• W3163046315 cites W3008443627 @default.
• W3163046315 cites W3008827533 @default.
• W3163046315 cites W3008874180 @default.
• W3163046315 cites W3012421327 @default.
• W3163046315 cites W3017468403 @default.
• W3163046315 cites W3021826725 @default.
• W3163046315 cites W3036209930 @default.
• W3163046315 cites W3041127941 @default.
• W3163046315 cites W3045079087 @default.
• W3163046315 cites W3060275525 @default.
• W3163046315 cites W3067080207 @default.
• W3163046315 cites W3072079143 @default.
• W3163046315 cites W3081555280 @default.
• W3163046315 cites W3085362418 @default.
• W3163046315 cites W3087102182 @default.
• W3163046315 cites W3120012695 @default.
• W3163046315 cites W3123444246 @default.
• W3163046315 cites W4236805817 @default.
• W3163046315 cites W4250812440 @default.
• W3163046315 doi "https://doi.org/10.1101/2021.05.19.21257429" @default.
• W3163046315 hasPublicationYear "2021" @default.
• W3163046315 type Work @default.
• W3163046315 sameAs 3163046315 @default.
• W3163046315 citedByCount "1" @default.
• W3163046315 countsByYear W31630463152023 @default.
• W3163046315 crossrefType "posted-content" @default.
• W3163046315 hasAuthorship W3163046315A5001774374 @default.
• W3163046315 hasAuthorship W3163046315A5002788561 @default.
• W3163046315 hasAuthorship W3163046315A5003776025 @default.
• W3163046315 hasAuthorship W3163046315A5008359642 @default.
• W3163046315 hasAuthorship W3163046315A5015765270 @default.
• W3163046315 hasAuthorship W3163046315A5019022859 @default.
• W3163046315 hasAuthorship W3163046315A5020347222 @default.
• W3163046315 hasAuthorship W3163046315A5028356335 @default.
• W3163046315 hasAuthorship W3163046315A5031356675 @default.
• W3163046315 hasAuthorship W3163046315A5041881696 @default.
• W3163046315 hasAuthorship W3163046315A5045767035 @default.
• W3163046315 hasAuthorship W3163046315A5047329575 @default.
• W3163046315 hasAuthorship W3163046315A5047891924 @default.
• W3163046315 hasAuthorship W3163046315A5051871773 @default.
• W3163046315 hasAuthorship W3163046315A5057785190 @default.
• W3163046315 hasAuthorship W3163046315A5062734602 @default.
• W3163046315 hasAuthorship W3163046315A5063111673 @default.
• W3163046315 hasAuthorship W3163046315A5067167406 @default.
• W3163046315 hasAuthorship W3163046315A5077983454 @default.
• W3163046315 hasAuthorship W3163046315A5079525487 @default.
• W3163046315 hasAuthorship W3163046315A5079571574 @default.
• W3163046315 hasAuthorship W3163046315A5081565688 @default.
• W3163046315 hasAuthorship W3163046315A5082379608 @default.
• W3163046315 hasAuthorship W3163046315A5087978819 @default.
• W3163046315 hasAuthorship W3163046315A5089247413 @default.
• W3163046315 hasBestOaLocation W31630463151 @default.
• W3163046315 hasConcept C126322002 @default.
• W3163046315 hasConcept C142724271 @default.
• W3163046315 hasConcept C159047783 @default.
• W3163046315 hasConcept C168563851 @default.
• W3163046315 hasConcept C197934379 @default.
• W3163046315 hasConcept C204787440 @default.
• W3163046315 hasConcept C2522874641 @default.
• W3163046315 hasConcept C27081682 @default.
• W3163046315 hasConcept C2775999097 @default.
• W3163046315 hasConcept C2776408679 @default.

• next